Bibliografia |
|
|
- Calvaruso V, et al. Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database. AASLD 2016 Poster 942
- Christensen S et al. Comorbidities, co-medication and potential drug to drug interactions in chronic hepatitis C patients (CHC): implications for adequate HCV treatment selection - data from a large transversal study in Germany and France. AASLD 2016. Poster 1971
- Koskinas J, et al. Efficacy and safety of direct acting antiviral(s) (DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience. AASLD 2016. Poster 2026
- Lionetti R et al. Daclatasvir in combination with other DAAs achieves high rate of virological clearance with excellent safety profile in liver tranplanted patients for hepatitis C. AASLD 2016. Poster 1633
- Madonia S, et al. Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort. AASLD 2016 Poster 1930
- Mauss S, et al. Effectiveness of DACLATASVIR plus SOFOSBUVIR in HCV-GT3 patients – Results from the German Hepatitis C Registry (DHC-R). AASLD 2016 Poster 932
- Milan M, et al. Efficacy and safety of DAA-based oral therapy in a large cohort of HCV patients treated in clinical practice in Italy and monitored by the NAVIGATORE web-platform. AASLD 2016 Poster 960
- Pasulo L, et al. Genotype 3 infection in DAA era: preliminary reports of a real life Northern Italy Network For Viral Hepati-ti. AASLD 2016. Poster 1934
- Romano A, et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. AASLD 2016. Oral presentation 19
- Welzel TM, et al. Real-World Effectiveness and Safety of DAA Combination Therapies in Elderly Patients > 70 Years of Age in the German Hepatitis C-Registry (DHC-R). AASLD 2016 Poster 951
|